<DOC>
	<DOCNO>NCT02362646</DOCNO>
	<brief_summary>The main purpose research determine whether inject mesenchymal precursor cell ( MPC ) heart surgery implant leave ventricular assist device ( LVAD ) safe . MPCs normally present human bone marrow show increase development blood vessel new heart muscle cell heart . In addition , research do test whether inject MPCs heart effective improve heart function .</brief_summary>
	<brief_title>Safety &amp; Efficacy Intramyocardial Injection Mesenchymal Precursor Cells Myocardial Function LVAD Recipients</brief_title>
	<detailed_description>Intramyocardial injection mesenchymal precursor cell ( MPC ) patient advanced heart failure treat leave ventricular assist device ( LVAD ) implantation may result renewable source proliferate functional cardiomyocytes ; induce development capillary larger-size blood vessel supply oxygen nutrient endogenous myocardium newly-implanted cardiomyocytes ; release factor capable paracrine signaling .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Ventricular Dysfunction</mesh_term>
	<criteria>Signed informed consent , inclusive release medical information , Health Insurance Portability Accountability Act ( HIPAA ) documentation Age 18 year old If subject partner childbearing potential , must willing use adequate contraception ( hormonal barrier method abstinence ) time screen period least 16 week procedure Female subject childbearing potential must negative serum pregnancy test screening Admitted clinical center time randomization Clinical indication accept candidate implantation FDAapproved ( US sit ) Health Canadaapproved ( Canadian sit ) implantable , nonpulsatile LVAD bridge transplantation destination therapy . Planned percutaneous LVAD implantation Anticipated requirement biventricular mechanical support Concomitant arrhythmia ablation time LVAD implantation Planned aortic valve intervention aortic insufficiency time LVAD implantation Cardiothoracic surgery within 30 day prior randomization Spontaneous myocardial infarction relate ischemia due primary coronary event unstable plaque rupture , erosion dissection within 30 day prior randomization Prior cardiac transplantation , LV reduction surgery , cardiomyoplasty Acute reversible cause heart failure ( e.g . myocarditis , profound hypothyroidism ) Stroke within 30 day prior randomization Platelet count &lt; 100,000/ul within 24 hour prior randomization Acute infectious process : acute bacterial , fungal , viral disease OR acute exacerbation chronic infectious disease hepatitis Presence &gt; 10 % antiHLA antibody titer know specificity MPC donor HLA antigens A known hypersensitivity dimethyl sulfoxide ( DMSO ) , murine , and/or bovine product History know active malignancy within past 3 year except localized prostate cancer , cervical carcinoma situ , breast cancer situ , nonmelanoma skin cancer definitively treat Presence human immunodeficiency virus ( HIV ) Received investigational intervention within 30 day prior randomization Treatment and/or incomplete followup treatment investigational cell base therapy within 6 month prior randomization Active participation research therapy cardiovascular repair/regeneration Prior recipient stem precursor cell therapy cardiac repair Pregnant breastfeeding time randomization . History know suspect hypercoagulable state opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Heart Failure</keyword>
	<keyword>Left Ventricular Assist Device</keyword>
	<keyword>Heart Transplantation</keyword>
	<keyword>Cardiomyopathy , Destination Therapy</keyword>
	<keyword>Cell Therapy</keyword>
	<keyword>Bridge Transplant</keyword>
</DOC>